We are developing therapeutics that target senescence and adjacent biology with broad application across multiple indications with established endpoints and well-defined regulatory pathways to approval. Our initial focus is on delivering localized therapy in ophthalmologic and neurologic diseases.



UNITY is pursuing multiple approaches to target novel biology in eye diseases. UBX1325, a potent Bcl-xL inhibitor, is currently being evaluated for the treatment of age-related diseases of the eye – including diabetic macular edema, diabetic retinopathy, and age-related macular degeneration. The small molecule targets proteins that senescent cells rely on for survival. A Phase 1 study is exploring the safety and tolerability of UBX1325 in patients with diabetic macular edema or age-related macular degeneration. The initial assessment of patients in this study did not reveal any dose limiting toxicities or treatment-emergent adverse events, supporting initiation of a Phase 2a proof-of-concept study in DME to evaluate the safety and efficacy of UBX1325. Initial data from this Phase 2a study is expected in the first half of 2022. UBX1967 remains in the portfolio as a molecularly distinct backup to UBX1325.

UNITY is also developing a novel antibody with a unique mechanism of action that activates the Tie2 pathway in age-related eye diseases. Tie2 pathway activity decreases with age and leads to the loss of vascular barrier integrity and diseased blood vessel formation in the eye. UNITY’s Tie2 activator, UBX2050, aims to restore healthy vasculature and function in diabetic macular edema, independent of Bcl-xL inhibition.

UNITY’s neurology programs build upon our foundational cellular senescence research platform to target core features of neurodegenerative diseases and cognitive disorders. These programs will focus on developing senolytic therapies for neurological diseases and complement the on-going exploration of novel mechanisms for cognitive benefit, including α-Klotho, UBX2089.

Our other research programs will also explore therapeutic modalities beyond small molecule approaches to significantly expand the target space for modulating senescent cell biology implicated as drivers of age-related diseases.




UBX1325, a potent Bcl-xL inhibitor, is in clinical development for the treatment of age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR). UBX1325 is designed to selectively eliminate the senescent cells accumulating in diseased blood vessels of the eye. This novel approach to eye disease has the potential to target diseased vasculature while leaving healthy blood vessels intact, reestablish barrier function in the eye, and reverse progression of disease. UNITY’s goal with UBX1325 is to transformationally improve real-world outcomes for patients with DR, DME, and AMD.


Retinal Bcl-xL inhibition

UBX1325 is the first senolytic approach intended to target senescent cells and selectively eliminate these cells in and around diseased vasculature in the eye, while leaving healthy blood vessels intact. UBX1325 is a novel senolytic small molecule inhibitor of Bcl-xL, a member of the Bcl-2 family of apoptosis regulatory proteins that is highly expressed in pathological blood vessels in the retina. Inhibition of Bcl-xL promotes apoptosis of diseased senescent cells, which accumulate in the retina, promoting inflammation and compromising vascular integrity. In preclinical research published in Cell Metabolism, a single dose of UNITY’s Bcl-xL small molecule inhibitor led to selective elimination of senescent cells in diseased vasculature, while enabling functional, healthy blood vessels to reorganize and regenerate.



According to the National Eye Institute, diabetic retinopathy is the most prominent complication of diabetes and the leading cause of blindness in working age individuals. NEI estimates that ~8 million Americans are afflicted by the eye disease and predicts the incidence will double over the next 15 years. In diabetic retinopathy, the small caliber blood vessels that feed the back of the eye (retina) degenerate and re-grow in an abnormal manner. These diseased vessels obstruct light and can leave scars in the retina. Diabetic macular edema is a common complication of diabetic retinopathy and the leading cause of blindness in adults with diabetes.

During the course of diabetes, cells that make up the small caliber blood vessels in the eye are more likely to become senescent. We believe these senescent vascular cells compromise the integrity of the blood vessel and release inflammatory factors that collectively compromise healthy vasculature. In DME, the damaged blood vessels leak into the retina, resulting in the accumulation of fluid in the macula – or the central part of the retina. Over time, the macula swells and may lead to severe vision loss.

One of the limitations of the current standard of care, anti-VEGF therapy, for vascular diseases of the retina is that they target both sick and healthy parts of the eye and hence can potentially impair normal remodeling of healthy vessels. Anti-VEGF agents, for example, block all blood vessel growth. Bcl-xL inhibition may be the key to a new class of neovascular treatments that provide a viable and much needed alternative to current treatment modalities.

UNITY is currently conducting the following clinical studies:
  • Phase 1 study evaluating a single dose of UBX1325 in patients with diabetic macular edema or age-related macular degeneration (NCT04537884)
  • Phase 2a study evaluating the safety and efficacy of UBX1325 in patients with diabetic macular edema (NCT04857996)
For patients or physicians interested in learning more about the studies, please visit